BriaCell (BCTX) Therapeutics will be presenting positive Phase 2 survival, and Phase 3 biomarker data across three clinical posters at the 2025 San Antonio Breast Cancer Symposium taking place December 9-12, 2025 at Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, Texas. “Our survival and biomarker data at SABCS is very encouraging because it underscores the potential of our novel immunotherapy and precision medicine to treat cancer patients,” stated William Williams, MD, BriaCell’s President & CEO. “We remain committed to improve survival and clinical outcomes in cancer patients whose medical needs remain unmet.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell announces publication with preliminary Phase 1b expansion cohort data
- BriaCell Therapeutics to Present Promising Clinical Data at SABCS 2025
- BriaCell and Receptor.AI Collaborate on AI-Driven Cancer Therapeutics
- BriaCell, Receptor.AI collaborate on AI small molecular cancer therapeutics
- BriaCell to Present Key Clinical Data at SABCS 2025